BCMA-Specific CAR Signaling Architecture for Sustained T-Cell Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chimeric antigen receptors (CARs) targeting B-cell maturation antigen (BCMA) have limitations in providing prolonged expansion and anti-tumor activity, particularly in treating BCMA-expressing cancers like multiple myeloma.
Innovation Solution
Development of BCMA-specific chimeric antigen receptors comprising an extracellular ligand-binding domain, hinge, transmembrane domain, and cytoplasmic domain with costimulatory and signaling domains, specifically designed to enhance T-cell cytotoxicity and persistence, using sequences such as anti-BCMA scFv, CD8 hinge, 4-1BB costimulatory, and CD3zeta signaling domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first generation CARs with CD3zeta or Fc receptor gamma signaling domains are used, then T-cell cytotoxicity redirection is achieved, but prolonged expansion and anti-tumor activity are not provided
Solution Approach 1:
The patent combines multiple signaling domains (CD3zeta for activation, 4-1BB for costimulation and survival, and CD28 for additional costimulation) into a single CAR construct. This merging of signaling pathways provides both immediate cytotoxicity redirection and sustained T-cell expansion through complementary mechanisms, resolving the contradiction between achieving cytotoxicity and maintaining prolonged activity.
Solution Approach 2:
The CAR construct uses a composite structure integrating extracellular antigen-binding domain (anti-BCMA scFv), hinge region (CD8), transmembrane domain (CD8), and multiple cytoplasmic signaling domains (CD3zeta, 4-1BB, CD28). This composite design combines the functional benefits of different molecular components to achieve both potent cytotoxicity and prolonged T-cell persistence.
2Measurement precision
If BCMA-specific CARs are developed to target malignant plasma cells, then specific targeting and T cell-mediated killing is achieved, but therapeutic efficacy needs enhancement
Solution Approach 1:
The patent employs an anti-BCMA single-chain variable fragment (scFv) derived from antibody 1F11 as the extracellular domain, providing highly specific local recognition of BCMA on malignant plasma cells. This specific antigen-binding region ensures precise targeting while the rest of the CAR structure provides the necessary signaling functions for effective killing.
Solution Approach 2:
The patent merges specific antigen recognition (anti-BCMA scFv) with multiple signaling domains (CD3zeta for activation, 4-1BB for costimulation and survival, CD28 for additional costimulation) to enhance therapeutic efficacy. The combination ensures both specific targeting and potent, sustained anti-tumor activity.
Data Source
Figure 1
AI summary
B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.